Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Section 6 of 6

References

291 sources

  1. Achenbach and Saft (2021) (opens in a new tab)
  2. Aetna clinical policy bulletin 1073 (2026) (opens in a new tab)
  3. Ajitkumar et al. (2025) (opens in a new tab)
  4. American Academy of Neurology (2022) (opens in a new tab)
  5. American Academy of Neurology movement disorders quality measures (opens in a new tab)
  6. Anderson et al. (2018) (opens in a new tab)
  7. Andriessen et al. (2025) (opens in a new tab)
  8. Armstrong and Miyasaki (2012) (opens in a new tab)
  9. Austedo prescribing information (2025) (opens in a new tab)
  10. Bachoud-Lévi et al. (2019) (opens in a new tab)
  11. Baig et al. (2016) (opens in a new tab)
  12. Bardakjian et al. (2019) (opens in a new tab)
  13. Barer et al. (2023) (opens in a new tab)
  14. Bates et al. (2015) (opens in a new tab)
  15. Bayen et al. (2023) (opens in a new tab)
  16. Bean et al. (2014) (opens in a new tab)
  17. Bell (2026) (opens in a new tab)
  18. BioMarin statement, ROCTAVIAN market withdrawal (2026) (opens in a new tab)
  19. Blank (2023) (opens in a new tab)
  20. Boareto et al. (2025) (opens in a new tab)
  21. Boersema-Wijma et al. (2023) (opens in a new tab)
  22. Bombard et al. (2009) (opens in a new tab)
  23. Bruzelius et al. (2019) (opens in a new tab)
  24. Burgunder et al. (2011) (opens in a new tab)
  25. Byrne et al. (2017) (opens in a new tab)
  26. Caldeira Brás et al. (2026) (opens in a new tab)
  27. Carlozzi et al. (2016) (opens in a new tab)
  28. Carlozzi et al. (2017) (opens in a new tab)
  29. Caron et al. (2020) (opens in a new tab)
  30. Chen et al. (2024) (opens in a new tab)
  31. Christensen et al. (2022) (opens in a new tab)
  32. Claassen et al. (2017) (opens in a new tab)
  33. Claassen et al. (2021) (opens in a new tab)
  34. Claassen et al. (2022) (opens in a new tab)
  35. ClinicalTrials.gov NCT03628235 (opens in a new tab)
  36. ClinicalTrials.gov NCT04120493 (opens in a new tab)
  37. ClinicalTrials.gov NCT04120493 version 1 (opens in a new tab)
  38. ClinicalTrials.gov NCT04120493 version 33 (opens in a new tab)
  39. ClinicalTrials.gov NCT05243017 (opens in a new tab)
  40. ClinicalTrials.gov NCT05243017 version 1 (opens in a new tab)
  41. CMS Cell and Gene Therapy Access Model (2026) (opens in a new tab)
  42. Coppen and Roos (2017) (opens in a new tab)
  43. Crowell et al. (2021) (opens in a new tab)
  44. CTIS 2024-511766-37-00 (opens in a new tab)
  45. da Silva van der Laan et al. (2024) (opens in a new tab)
  46. DailyMed AUSTEDO prescribing information (2025) (opens in a new tab)
  47. DailyMed INGREZZA prescribing information (2026) (opens in a new tab)
  48. DailyMed XENAZINE prescribing information (2019) (opens in a new tab)
  49. Divino et al. (2013) (opens in a new tab)
  50. Dorey et al. (2016) (opens in a new tab)
  51. Ekkel et al. (2023) (opens in a new tab)
  52. El-Sourady et al. (2022) (opens in a new tab)
  53. EMA orphan designation EU/3/17/1957 (2018) (opens in a new tab)
  54. EMA questions and answers on withdrawal of Nurzigma application (2025) (opens in a new tab)
  55. Erwin et al. (2010) (opens in a new tab)
  56. Estevez-Fraga et al. (2021) (opens in a new tab)
  57. EU Clinical Trials Register 2020-001461-36 (opens in a new tab)
  58. Evans et al. (2013) (opens in a new tab)
  59. Evers et al. (2018) (opens in a new tab)
  60. Exuzides et al. (2021) (opens in a new tab)
  61. Exuzides et al. (2022a) (opens in a new tab)
  62. Exuzides et al. (2022b) (opens in a new tab)
  63. Exuzides et al. (2022c) (opens in a new tab)
  64. Farag et al. (2026a) (opens in a new tab)
  65. Farag et al. (2026b) (opens in a new tab)
  66. FDA externally controlled trials draft guidance (2023) (opens in a new tab)
  67. FDA Kebilidi summary basis for regulatory action (2024) (opens in a new tab)
  68. FDA long term follow-up after gene therapy guidance (2020) (opens in a new tab)
  69. FDA orphan drug designation record for AMT-130 (2017) (opens in a new tab)
  70. Ferreira et al. (2022) (opens in a new tab)
  71. Fisher and Hayden (2014) (opens in a new tab)
  72. Frank et al. (2025) (opens in a new tab)
  73. Frisch et al. (2026) (opens in a new tab)
  74. Furby et al. (2022) (opens in a new tab)
  75. Furr Stimming et al. (2023) (opens in a new tab)
  76. Furr Stimming et al. (2025) (opens in a new tab)
  77. Furr Stimming et al. (2026) (opens in a new tab)
  78. Fusilli et al. (2018) (opens in a new tab)
  79. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2015) (opens in a new tab)
  80. Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium (2019) (opens in a new tab)
  81. Gokhale and Villa Zapata (2025) (opens in a new tab)
  82. Grimbergen et al. (2008) (opens in a new tab)
  83. Guzauskas et al. (2024) (opens in a new tab)
  84. Hagen (2023) (opens in a new tab)
  85. Hall et al. (2025) (opens in a new tab)
  86. Handsaker et al. (2025) (opens in a new tab)
  87. Harding (2026) (opens in a new tab)
  88. Harrison et al. (2023) (opens in a new tab)
  89. Hawkins et al. (2013) (opens in a new tab)
  90. Hawton et al. (2019) (opens in a new tab)
  91. Heemskerk and Roos (2012) (opens in a new tab)
  92. Helfand (2019) (opens in a new tab)
  93. Hensman Moss et al. (2017) (opens in a new tab)
  94. Hergert et al. (2021) (opens in a new tab)
  95. Hernandez (2024) (opens in a new tab)
  96. Hernandez (2025) (opens in a new tab)
  97. Herzog-Krzywoszanska and Krzywoszanski (2019) (opens in a new tab)
  98. Ho et al. (2009) (opens in a new tab)
  99. Hubers et al. (2012) (opens in a new tab)
  100. Hubers et al. (2013) (opens in a new tab)
  101. Huntington Study Group (1996) (opens in a new tab)
  102. Huntington Study Group (2006) (opens in a new tab)
  103. Huntington Study Group (2016) (opens in a new tab)
  104. Huntington's Disease Society of America (2011) (opens in a new tab)
  105. Huntington's Disease Society of America (2020) (opens in a new tab)
  106. Huntington's Disease Society of America Centers of Excellence (opens in a new tab)
  107. Huntington's Disease Society of America genetic testing and your rights (opens in a new tab)
  108. ICER (2026) (opens in a new tab)
  109. ICER draft scope (2026) (opens in a new tab)
  110. ICER Huntington's disease assessment page (2026) (opens in a new tab)
  111. ICER model analysis plan (2026) (opens in a new tab)
  112. ICER public comments on draft scope (2026) (opens in a new tab)
  113. ICER research protocol (2026) (opens in a new tab)
  114. ICER revised scope (2026) (opens in a new tab)
  115. ICER single and short-term therapies adaptations (2022) (opens in a new tab)
  116. Inbar et al. (2026) (opens in a new tab)
  117. Ingrezza prescribing information (2026) (opens in a new tab)
  118. Jahanshahi et al. (2021) (opens in a new tab)
  119. Johnson et al. (2018) (opens in a new tab)
  120. Jones et al. (2016) (opens in a new tab)
  121. Kachian et al. (2019) (opens in a new tab)
  122. Kay et al. (2016) (opens in a new tab)
  123. Kebilidi prescribing information (2024) (opens in a new tab)
  124. Keskin et al. (2019) (opens in a new tab)
  125. Keum et al. (2016) (opens in a new tab)
  126. Kim et al. (2024a) (opens in a new tab)
  127. Kim et al. (2024b) (opens in a new tab)
  128. Knott et al. (2024) (opens in a new tab)
  129. Ko et al. (2020) (opens in a new tab)
  130. Langbehn et al. (2004) (opens in a new tab)
  131. Langbehn et al. (2019) (opens in a new tab)
  132. Lee et al. (2022) (opens in a new tab)
  133. Lee et al. (2024) (opens in a new tab)
  134. Liu (2025) (opens in a new tab)
  135. MacLeod et al. (2013) (opens in a new tab)
  136. Marder et al. (2000) (opens in a new tab)
  137. Margolin et al. (2026) (opens in a new tab)
  138. Martinez-Horta et al. (2016) (opens in a new tab)
  139. Massey et al. (2021) (opens in a new tab)
  140. McColgan and Tabrizi (2018) (opens in a new tab)
  141. McColgan et al. (2023) (opens in a new tab)
  142. McLean et al. (2024) (opens in a new tab)
  143. Medina et al. (2022) (opens in a new tab)
  144. MedlinePlus (2020) (opens in a new tab)
  145. Mestre et al. (2009a) (opens in a new tab)
  146. Mestre et al. (2009b) (opens in a new tab)
  147. Mestre et al. (2018a) (opens in a new tab)
  148. Mestre et al. (2018b) (opens in a new tab)
  149. MHRA paediatric investigation plan waiver decision (2026) (opens in a new tab)
  150. Mills et al. (2024) (opens in a new tab)
  151. Miniarikova et al. (2016) (opens in a new tab)
  152. Miniarikova et al. (2017) (opens in a new tab)
  153. Miniarikova et al. (2018) (opens in a new tab)
  154. Minikel (2025) (opens in a new tab)
  155. Morais et al. (2022) (opens in a new tab)
  156. Morrison et al. (2011) (opens in a new tab)
  157. Mühlbäck et al. (2023) (opens in a new tab)
  158. Myshko (2022) (opens in a new tab)
  159. Myshko (2023) (opens in a new tab)
  160. Myshko (2024) (opens in a new tab)
  161. NINDS (2026) (opens in a new tab)
  162. Ogilvie et al. (2025) (opens in a new tab)
  163. Ogilvie et al. (2026) (opens in a new tab)
  164. Ohlmeier et al. (2019) (opens in a new tab)
  165. Oosterloo et al. (2024) (opens in a new tab)
  166. Oster et al. (2008) (opens in a new tab)
  167. Patel et al. (2023) (opens in a new tab)
  168. Patil et al. (2025) (opens in a new tab)
  169. Patil et al. (2026) (opens in a new tab)
  170. Paulsen et al. (2001) (opens in a new tab)
  171. Paulsen et al. (2014) (opens in a new tab)
  172. Pfizer press release, BEQVEZ approval (2024) (opens in a new tab)
  173. Phares et al. (2024) (opens in a new tab)
  174. Pollard et al. (2024) (opens in a new tab)
  175. Poprelka et al. (2025) (opens in a new tab)
  176. Pringsheim et al. (2012) (opens in a new tab)
  177. PTC Therapeutics (2026) (opens in a new tab)
  178. Quinn et al. (2020) (opens in a new tab)
  179. Rawlins et al. (2016) (opens in a new tab)
  180. Reilmann (2013) (opens in a new tab)
  181. Reilmann et al. (2014) (opens in a new tab)
  182. Reilmann et al. (2025) (opens in a new tab)
  183. Richardson et al. (2020) (opens in a new tab)
  184. Roche (2021) (opens in a new tab)
  185. Rodrigues and Ferreira (2017b) (opens in a new tab)
  186. Rodrigues et al. (2017a) (opens in a new tab)
  187. Rodrigues et al. (2020) (opens in a new tab)
  188. Rodriguez Santana et al. (2022) (opens in a new tab)
  189. Rodríguez Santana et al. (2025) (opens in a new tab)
  190. Rodríguez-Santana et al. (2021) (opens in a new tab)
  191. Rodríguez-Santana et al. (2023) (opens in a new tab)
  192. Roiboit and Stout (2026) (opens in a new tab)
  193. Roos (2010) (opens in a new tab)
  194. Saft et al. (2023) (opens in a new tab)
  195. Sampaio et al. (2024) (opens in a new tab)
  196. Sathe et al. (2021) (opens in a new tab)
  197. Sawant et al. (2024) (opens in a new tab)
  198. Schobel et al. (2017) (opens in a new tab)
  199. Sellers et al. (2020) (opens in a new tab)
  200. Shaw et al. (2022a) (opens in a new tab)
  201. Shaw et al. (2022b) (opens in a new tab)
  202. Silva-Paredes et al. (2019) (opens in a new tab)
  203. Smith et al. (2026) (opens in a new tab)
  204. Snowden (2017) (opens in a new tab)
  205. Sogorb-Gonzalez et al. (2021) (opens in a new tab)
  206. Sogorb-Gonzalez et al. (2024) (opens in a new tab)
  207. Sokol et al. (2022) (opens in a new tab)
  208. Sokol et al. (2023) (opens in a new tab)
  209. Solberg et al. (2018) (opens in a new tab)
  210. Spronck et al. (2019) (opens in a new tab)
  211. Spronck et al. (2021) (opens in a new tab)
  212. Stoker et al. (2022) (opens in a new tab)
  213. Tabrizi et al. (2011) (opens in a new tab)
  214. Tabrizi et al. (2013) (opens in a new tab)
  215. Tabrizi et al. (2020) (opens in a new tab)
  216. Tabrizi et al. (2022) (opens in a new tab)
  217. Tarolli et al. (2017) (opens in a new tab)
  218. Thomson et al. (2023) (opens in a new tab)
  219. Thorley et al. (2018) (opens in a new tab)
  220. To et al. (2022) (opens in a new tab)
  221. To et al. (2023) (opens in a new tab)
  222. Trundell et al. (2018) (opens in a new tab)
  223. Trundell et al. (2019) (opens in a new tab)
  224. uniQure expanded access policy (2024) (opens in a new tab)
  225. uniQure Form 10-K (2026) (opens in a new tab)
  226. uniQure Form 10-Q, third quarter 2026 (2026) (opens in a new tab)
  227. uniQure Huntington's disease program page (opens in a new tab)
  228. uniQure Phase I/II clinical trial page (opens in a new tab)
  229. uniQure presentation, four-year data (2026) (opens in a new tab)
  230. uniQure presentation, three-year topline results (2025) (opens in a new tab)
  231. uniQure press release, 24-month interim data (2024) (opens in a new tab)
  232. uniQure press release, BLA plan after Type B meeting (2026) (opens in a new tab)
  233. uniQure press release, BLA submission (2026) (opens in a new tab)
  234. uniQure press release, clinical update on first patients (2021) (opens in a new tab)
  235. uniQure press release, closing of sale to Genezen (2024) (opens in a new tab)
  236. uniQure press release, debt refinancing (2025) (opens in a new tab)
  237. uniQure press release, enrollment of first two cohorts (2022) (opens in a new tab)
  238. uniQure press release, FDA acceptance of BLA (2026) (opens in a new tab)
  239. uniQure press release, FDA alignment on accelerated approval (2024) (opens in a new tab)
  240. uniQure press release, FDA Fast Track designation (2019) (opens in a new tab)
  241. uniQure press release, FDA RMAT designation (2024) (opens in a new tab)
  242. uniQure press release, first European patients dosed (2022) (opens in a new tab)
  243. uniQure press release, first patients treated (2020) (opens in a new tab)
  244. uniQure press release, first quarter 2025 results (2025) (opens in a new tab)
  245. uniQure press release, four-year data (2026) (opens in a new tab)
  246. uniQure press release, full year 2022 results (2023) (opens in a new tab)
  247. uniQure press release, full year 2023 results (2024) (opens in a new tab)
  248. uniQure press release, full year 2025 results (2026) (opens in a new tab)
  249. uniQure press release, IND clearance (2019) (opens in a new tab)
  250. uniQure press release, interim data update (2023) (opens in a new tab)
  251. uniQure press release, low-dose cohort update (2022) (opens in a new tab)
  252. uniQure press release, MHRA pre-submission meeting (2026) (opens in a new tab)
  253. uniQure press release, pre-BLA meeting feedback (2025) (opens in a new tab)
  254. uniQure press release, pre-BLA meeting minutes (2025) (opens in a new tab)
  255. uniQure press release, preclinical publication (2019) (opens in a new tab)
  256. uniQure press release, preclinical publications (2021) (opens in a new tab)
  257. uniQure press release, sale of manufacturing facility to Genezen (2024) (opens in a new tab)
  258. uniQure press release, second quarter 2022 results (2022) (opens in a new tab)
  259. uniQure press release, second quarter 2025 results (2025) (opens in a new tab)
  260. uniQure press release, second quarter 2026 results (2026) (opens in a new tab)
  261. uniQure press release, statistical analysis plan and CMC alignment (2025) (opens in a new tab)
  262. uniQure press release, third quarter 2022 results (2022) (opens in a new tab)
  263. uniQure press release, third quarter 2025 results (2025) (opens in a new tab)
  264. uniQure press release, third quarter 2026 results (2026) (opens in a new tab)
  265. uniQure press release, three-year topline results (2025) (opens in a new tab)
  266. uniQure press release, Type A meeting minutes (2026) (opens in a new tab)
  267. uniQure press release, Type A meeting scheduled (2026) (opens in a new tab)
  268. uniQure press release, U.S. interim data (2023) (opens in a new tab)
  269. Vallès et al. (2021) (opens in a new tab)
  270. van der Bent et al. (2022) (opens in a new tab)
  271. van der Zwaan et al. (2022) (opens in a new tab)
  272. van Walsem et al. (2022) (opens in a new tab)
  273. Vonsattel et al. (1985) (opens in a new tab)
  274. Walker (2007) (opens in a new tab)
  275. Watkins et al. (2018) (opens in a new tab)
  276. Wesson et al. (2018) (opens in a new tab)
  277. Wexler et al. (2016) (opens in a new tab)
  278. Wheelock et al. (2003) (opens in a new tab)
  279. WHO Proposed INN List 125 (2021) (opens in a new tab)
  280. Willock et al. (2021) (opens in a new tab)
  281. Willock et al. (2023) (opens in a new tab)
  282. Wilson et al. (2024) (opens in a new tab)
  283. Winder et al. (2018) (opens in a new tab)
  284. Xenazine prescribing information (2017) (opens in a new tab)
  285. Yohrling et al. (2019) (opens in a new tab)
  286. Yohrling et al. (2020) (opens in a new tab)
  287. Young et al. (2026) (opens in a new tab)
  288. Youssov et al. (2022) (opens in a new tab)
  289. Youssov et al. (2025) (opens in a new tab)
  290. Yu et al. (2019) (opens in a new tab)
  291. Zhang et al. (2025) (opens in a new tab)